Asensus Surgical has received 510(k) clearance from the FDA for an expanded indication to treat adult and pediatric Urology patients with the Senhance Surgical System. While the Senhance System has been utilized for Urology procedures outside the U.S. for several years, this expanded indication will open the door to this specialty to leverage the advantages of the Senhance System in the U.S. patient population.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASXC:
- Asensus Surgical Announces LKH-Universitätsklinikum Graz Hospital in Austria to Initiate Senhance Surgery Program
- Asensus Surgical’s Senhance Surgery System selected by Austrian hospital
- Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program
- Asensus Surgical: St. Marianna University to lease Senhance Surgical System
- KARL STORZ to acquire Asensus for 35c per share in cash
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue